NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing (NGS) in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, weigh in on the benefits of NGS.
- Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and others share insights on NGS and treatment planning.
- Additional experts, such as Naval G. Daver, MD, and Jessica Altman, MD, contribute to the discussion.
The use of NGS streamlines biomarker testing, enabling more effective treatment planning for patients with solid tumors.
Authors include Estelamari Rodriguez, MD, MPH, Millie Das, MD, and Ruham Nasany, MD, among others.
In summary: NGS improves biomarker testing for solid tumors.